TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05020379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perioperative and postoperative multimodal analgesia
Description: Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Perioperative and postoperative multimodal analgesia
Description: Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
Study: NCT06214988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selective approach defunctioning stoma
Description: With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
Study: NCT05459376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises and dry cupping
Description: Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
Study: NCT05122650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP385
Description: JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP385
Description: JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP385
Description: JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
Study: NCT06190054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERAMIRT
Description: MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role
Study: NCT06246942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (spTMS)
Description: Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Description: Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
Study: NCT05122650

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
Study: NCT05459376

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercises and dry cupping
Description: Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
Study: NCT05148871

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikogen/Covax-19
Description: Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikogen/Covax-19
Description: Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikogen/Covax-19
Description: Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikogen/Covax-19
Description: Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
Study: NCT04952623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Related Shoulder Pain E-Learning Program
Description: The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Related Shoulder Pain E-Learning Program
Description: The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
Study: NCT05133830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: OCA will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: OCA will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: OCA will be administered
Study: NCT06229171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adherence support system based on a vocal assistant
Description: Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.
Study: NCT06309225

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified dose and fields intensity modulated radiotherapy
Description: Instead of standard bilateral or extensive neck fields, the current radiation fields will cover disease with only 3cm expansion. The clinical target volumes doses are biologically equivalent to the standard but given in a shorter hypofractionated approach.
Study: NCT05133830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: OCA will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Linerixibat will be administered
Study: NCT05312827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation
Description: The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
Study: NCT05133830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Linerixibat will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Linerixibat will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: Linerixibat will be administered
Study: NCT06240767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte infusion
Description: The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
Study: NCT05950152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Injection 30mg
Description: meloxicam injection 30mg every 24 hours for up to 2 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Injection 60mg
Description: meloxicam injection 60mg every 24 hours for up to 2 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: IV Placebo every 24 hours for up to 2 doses
Study: NCT04199702

Intervention type: OTHER
Group type: OTHER
Intervention: Same day discharge
Description: Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
Study: NCT05204303

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour pH-impedance monitoring
Description: Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour pH-impedance monitoring
Description: Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.

Intervention type: OTHER
Intervention: Symptom questionnaires
Description: Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)

Intervention type: OTHER
Intervention: Symptom questionnaires
Description: Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)

Intervention type: OTHER
Intervention: Symptom questionnaires
Description: Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)

Intervention type: OTHER
Intervention: ROME IV Diagnostic Questionnaire
Description: A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)

Intervention type: OTHER
Intervention: ROME IV Diagnostic Questionnaire
Description: A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)

Intervention type: OTHER
Intervention: ROME IV Diagnostic Questionnaire
Description: A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
Study: NCT05948384

Intervention type: OTHER
Group type: OTHER
Intervention: PNF
Description: For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
Study: NCT06450119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking training
Description: The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
Study: NCT05335889

Intervention type: DEVICE
Intervention: eButton
Description: The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
Study: NCT05072444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX7728
Description: beta lactamase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX2014
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX2014
Description: antibiotic
Study: NCT06248957

Intervention type: COMBINATION_PRODUCT
Intervention: Immunomodulation
Description: Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
Study: NCT06450119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking training
Description: The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognition training
Description: The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognition training
Description: The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
Study: NCT05030714

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Field Testing
Description: Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
Study: NCT05148884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLX-112
Description: NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
Study: NCT05188157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physiotherapy
Description: The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
Study: NCT05382000

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.
Description: After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center.
Study: NCT06339476

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum ADMA, MDA and M30 levels mesurment
Description: Blood samples collected from patienst, only 7 mL
Study: NCT05170776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates and postural correction exercise
Description: ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercises
Description: ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural correction exercises
Description: postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period.
Study: NCT06078800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-17231
Description: After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
Study: NCT05221502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid + Bedaquiline + OPC-167832 10 mg
Description: Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (10 mg QD) for 17 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid + Bedaquiline + OPC-167832 30 mg
Description: Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (30 mg QD) for 17 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid + Bedaquiline + OPC-167832 90 mg
Description: Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RHEZ
Description: RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
Study: NCT04645277

Intervention type: DEVICE
Intervention: Scanning with magnetic resonance imaging
Description: Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.

Intervention type: DEVICE
Intervention: Scanning with magnetic resonance imaging
Description: Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.